Cancer

GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23

Booth (#7326) will highlight new product introductions, key innovations, and AI-enabled advancements from the company’s comprehensive portfolio of Imaging, Ultrasound,…

12 months ago

TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughsCHICAGO, Nov. 26, 2023 (GLOBE NEWSWIRE) --…

12 months ago

At RSNA 2023, AGFA HealthCare Presents the Application of Generative AI in Radiology, as Well as New RUBEE(R) AI Specialty Packages

AGFA HealthCare will demonstrate the power of Enterprise Imaging innovations by showcasing new RUBEE® AI Packages and RUBEE® AI Integrations…

12 months ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

FLORHAM PARK, N.J., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a biotechnology company developing allogeneic…

12 months ago

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and CAN10

LUND, SE / ACCESSWIRE / November 24, 2023 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new…

12 months ago

Hologic to Showcase Developments in Next-Generation AI Solutions at RSNA 2023

Leader in Women’s Health Will Highlight New Imaging Solutions That Aid in Cancer Detection and Radiologist WorkflowMARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #genius3d--Hologic,…

12 months ago

Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule

ST. LOUIS, Nov. 23, 2023 (GLOBE NEWSWIRE) -- Curium, a global leader in nuclear medicine, announced today the successful completion…

12 months ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

12 months ago

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS…

12 months ago

Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19

SHANGHAI, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a…

12 months ago